299 related articles for article (PubMed ID: 32191225)
21. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M; Venkata PP; Viswanadhapalli S; Palacios B; Alejo S; Chen Y; He Y; Pratap UP; Liu J; Zou Y; Lai Z; Suzuki T; Brenner AJ; Tekmal RR; Vadlamudi RK; Sareddy GR
Breast Cancer Res Treat; 2021 Jan; 185(2):343-357. PubMed ID: 33057995
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
23. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
24. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
[TBL] [Abstract][Full Text] [Related]
25. p97/VCP is highly expressed in the stem-like cells of breast cancer and controls cancer stemness partly through the unfolded protein response.
Li C; Huang Y; Fan Q; Quan H; Dong Y; Nie M; Wang J; Xie F; Ji J; Zhou L; Zheng Z; Wang L
Cell Death Dis; 2021 Mar; 12(4):286. PubMed ID: 33731668
[TBL] [Abstract][Full Text] [Related]
26. Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug.
Vásquez-Bochm LX; Velázquez-Paniagua M; Castro-Vázquez SS; Guerrero-Rodríguez SL; Mondragon-Peralta A; De La Fuente-Granada M; Pérez-Tapia SM; González-Arenas A; Velasco-Velázquez MA
Pharmacol Rep; 2019 Jun; 71(3):535-544. PubMed ID: 31026757
[TBL] [Abstract][Full Text] [Related]
27. VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.
Kim M; Jang K; Miller P; Picon-Ruiz M; Yeasky TM; El-Ashry D; Slingerland JM
Oncogene; 2017 Sep; 36(36):5199-5211. PubMed ID: 28504716
[TBL] [Abstract][Full Text] [Related]
28. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer.
Tsang JY; Huang YH; Luo MH; Ni YB; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
Breast Cancer Res Treat; 2012 Nov; 136(2):407-17. PubMed ID: 23053657
[TBL] [Abstract][Full Text] [Related]
29. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.
Ithimakin S; Day KC; Malik F; Zen Q; Dawsey SJ; Bersano-Begey TF; Quraishi AA; Ignatoski KW; Daignault S; Davis A; Hall CL; Palanisamy N; Heath AN; Tawakkol N; Luther TK; Clouthier SG; Chadwick WA; Day ML; Kleer CG; Thomas DG; Hayes DF; Korkaya H; Wicha MS
Cancer Res; 2013 Mar; 73(5):1635-46. PubMed ID: 23442322
[TBL] [Abstract][Full Text] [Related]
30. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.
Zhao D; Pan C; Sun J; Gilbert C; Drews-Elger K; Azzam DJ; Picon-Ruiz M; Kim M; Ullmer W; El-Ashry D; Creighton CJ; Slingerland JM
Oncogene; 2015 Jun; 34(24):3107-19. PubMed ID: 25151964
[TBL] [Abstract][Full Text] [Related]
31. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
[TBL] [Abstract][Full Text] [Related]
32. Transfection of T-Box Transcription Factor
Akimoto N; Nakamura K; Hijioka H; Kume K; Matsumura Y; Sugiura T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453543
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional repressor GATA binding 1-mediated repression of SRY-box 2 expression suppresses cancer stem cell functions and tumor initiation.
Gong X; Liu W; Wu L; Ma Z; Wang Y; Yu S; Zhang J; Xie H; Wei G; Ma F; Lu L; Chen L
J Biol Chem; 2018 Nov; 293(48):18646-18654. PubMed ID: 30315105
[TBL] [Abstract][Full Text] [Related]
34. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.
Ginestier C; Monville F; Wicinski J; Cabaud O; Cervera N; Josselin E; Finetti P; Guille A; Larderet G; Viens P; Sebti S; Bertucci F; Birnbaum D; Charafe-Jauffret E
Stem Cells; 2012 Jul; 30(7):1327-37. PubMed ID: 22605458
[TBL] [Abstract][Full Text] [Related]
35. Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable
Mascaró C; Ortega A; Carceller E; Ruiz Rodriguez R; Ciceri F; Lunardi S; Yu L; Hilbert M; Maes T
J Biol Chem; 2019 May; 294(20):8311-8322. PubMed ID: 30804215
[TBL] [Abstract][Full Text] [Related]
36. YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells.
Jung K; Wu F; Wang P; Ye X; Abdulkarim BS; Lai R
BMC Cancer; 2014 May; 14():328. PubMed ID: 24885403
[TBL] [Abstract][Full Text] [Related]
37. Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness.
Omori H; Sato K; Nakano T; Wakasaki T; Toh S; Taguchi K; Nakagawa T; Masuda M
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2433-2444. PubMed ID: 31485767
[TBL] [Abstract][Full Text] [Related]
38. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
39. Molecular and functional interactions between AKT and SOX2 in breast carcinoma.
Schaefer T; Wang H; Mir P; Konantz M; Pereboom TC; Paczulla AM; Merz B; Fehm T; Perner S; Rothfuss OC; Kanz L; Schulze-Osthoff K; Lengerke C
Oncotarget; 2015 Dec; 6(41):43540-56. PubMed ID: 26498353
[TBL] [Abstract][Full Text] [Related]
40. DDX17 (P72), a Sox2 binding partner, promotes stem-like features conferred by Sox2 in a small cell population in estrogen receptor-positive breast cancer.
Alqahtani H; Gopal K; Gupta N; Jung K; Alshareef A; Ye X; Wu F; Li L; Lai R
Cell Signal; 2016 Feb; 28(2):42-50. PubMed ID: 26569340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
